A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 138 participants.
Also called NCT04175600
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 138 participants
- Sponsor
- Registry
-
NCT04175600 -
2019-002817-21 -
2022-501012-34-00
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Results first posted
- Countries
- United States, Australia, Belarus, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Finland, France, Germany, Hungary, Ireland, Israel, Italy, Lithuania, Malaysia, Mexico, Poland, Portugal, Russia, Serbia, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Türkiye, Ukraine, Vietnam
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT04175600. Randomized; double masking; primary purpose treatment. Start 2020-01-16 (actual); primary completion 2024-10-11 (actual). Results posted on 2026-07-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension
- Acronym
- SALTO
- Condition
- Hypertension, Pulmonary
- Intervention (Drug)
- Selexipag
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Standard of Care (SOC): Endothelin receptor antagonist
- Intervention (Drug)
- SOC: Phosphodiesterase type 5 (PDE-5) inhibitor
- Intervention (Drug)
- SOC: Soluble guanylate cyclase stimulator
- Lead sponsor
- Actelion
Record details
- Record id
cardio:ct-nct04175600- Content hash
8c546d47f62ff3fb6715108bf661eafc064d814978ab8700db891d633a48bd84